Objective The effect of dietary restriction, intense exercise and menstrual dysfunction on bone mineral density remains controversial. The aim of this study was to assess the skeletal health status and relationship be...Objective The effect of dietary restriction, intense exercise and menstrual dysfunction on bone mineral density remains controversial. The aim of this study was to assess the skeletal health status and relationship between bone mineral density and nutrient intake, menstrual status, estrogen level and other factos in Chinese adolescent dancers. Methods Sixty dancers and 77 healthy controls underwent measurements of bone density, body composition, and estrogen level. Nutrient intake, menstrual status and physical activity were assessed with questionnaires. The correlation between these factors were analyzed. Results The dancers under study had a significantly lean body mass index （18.3±1.4 kg/m^2 vs. 21.7±3.1 kg/m^2）, lower percentage of body fat （0.25±0.05 vs. 0.34±0.04） and later age at menarche （14.0±0.9 y vs. 13.0±1.3 y）, and the estrogen level, daily calorie and fat intake in them were also lower than in the controls. All the dancers undertook intensive physical activity every day and up to 69% of them suffered from irregular menarche. Yet they had relatively high BMD and BMC of the total body and legs than the controls after adjusting for BM1 and age. Site-specific BMD was positively correlated to BMI, body composition and training hours per week and negatively correlated to the age at menarche and menstrual frequency. Conclusions The relatively high BMD and BMC of the dancers at the total body and legs were probably caused by high levels of weight-bearing physical activity. To ameliorate disordered eating, especially low energy intake might be helpful to prevent the Triad and to improve the bone health in adolescent dancers.展开更多
<strong>Introduction</strong>:<span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Naturally based treatments for osteoporosis are...<strong>Introduction</strong>:<span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Naturally based treatments for osteoporosis are currently limited. The purpose of this investigation was to ascertain whether bovine colostrum supplementation can improve bone health in humans. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> In tot</span><span style="font-family:Verdana;"></span><span style="font-family:Verdana;">al 63 individuals volunteered in a 4-month supplementation project. They were stratified into three groups: </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">1</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) healthy post-menopausal women (n = 24)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">2</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) individuals with osteopenia (n = 25)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">3</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) people with osteoporosis (n = 14). Participants of each group were randomly assigned into two experimental sub-groups: </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">a</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) the bovine colostrum (BC) supplementation (200</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">mL/day;5 days/week)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">b</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) the placebo sub-group. Before and after the 4-month supplementation, blood samples were obtained and bone mineral density (BMD) was measured. Dual-Energy X-ray Absorptiometry (DXA) was performed on three different anatomical sites: lumbar spine (LS), left femur neck (FN), and left forearm (Arm). Bone health markers </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">(</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">bone alkaline phosphatase (BAP), osteocalcin, C-terminal telopeptide (CTX-I), deoxypyridinoline (DPD)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"> as well as immunological markers </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">(</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">interleukin 6 (IL6) and immunoglobulin E (IgE)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">)</span></span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, were assessed in blood serum with enzyme immunoassays, at baseline and</span><span><span style="font-family:Verdana;"> 4-months after BC supplementation. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> No significant </span></span><span style="font-family:Verdana;">changes were found in bone densitometry factors (p > 0.05), for all studied blood parameters and their calculated effect sizes. </span><b><span style="font-family:Verdana;">Conclusions:</span></b><span style="font-family:Verdana;"> It is concluded that, as studied herein, BC does not seem to affect human bone health. This pilot study though warrant the need for further research into the efficacy of BC in patients with osteoporosis.展开更多
基金supported by key projects of the national science & technology pillar program during the eleventh five-year plan period (2008BAI58B02)danone institute China diet nutrition & comunication grant proposal 2006(DIC 2006-4)
文摘Objective The effect of dietary restriction, intense exercise and menstrual dysfunction on bone mineral density remains controversial. The aim of this study was to assess the skeletal health status and relationship between bone mineral density and nutrient intake, menstrual status, estrogen level and other factos in Chinese adolescent dancers. Methods Sixty dancers and 77 healthy controls underwent measurements of bone density, body composition, and estrogen level. Nutrient intake, menstrual status and physical activity were assessed with questionnaires. The correlation between these factors were analyzed. Results The dancers under study had a significantly lean body mass index （18.3±1.4 kg/m^2 vs. 21.7±3.1 kg/m^2）, lower percentage of body fat （0.25±0.05 vs. 0.34±0.04） and later age at menarche （14.0±0.9 y vs. 13.0±1.3 y）, and the estrogen level, daily calorie and fat intake in them were also lower than in the controls. All the dancers undertook intensive physical activity every day and up to 69% of them suffered from irregular menarche. Yet they had relatively high BMD and BMC of the total body and legs than the controls after adjusting for BM1 and age. Site-specific BMD was positively correlated to BMI, body composition and training hours per week and negatively correlated to the age at menarche and menstrual frequency. Conclusions The relatively high BMD and BMC of the dancers at the total body and legs were probably caused by high levels of weight-bearing physical activity. To ameliorate disordered eating, especially low energy intake might be helpful to prevent the Triad and to improve the bone health in adolescent dancers.
文摘<strong>Introduction</strong>:<span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Naturally based treatments for osteoporosis are currently limited. The purpose of this investigation was to ascertain whether bovine colostrum supplementation can improve bone health in humans. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> In tot</span><span style="font-family:Verdana;"></span><span style="font-family:Verdana;">al 63 individuals volunteered in a 4-month supplementation project. They were stratified into three groups: </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">1</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) healthy post-menopausal women (n = 24)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">2</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) individuals with osteopenia (n = 25)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">3</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) people with osteoporosis (n = 14). Participants of each group were randomly assigned into two experimental sub-groups: </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">a</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) the bovine colostrum (BC) supplementation (200</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">mL/day;5 days/week)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">;</span></span><span><span style="font-family:;" "=""> </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">b</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">) the placebo sub-group. Before and after the 4-month supplementation, blood samples were obtained and bone mineral density (BMD) was measured. Dual-Energy X-ray Absorptiometry (DXA) was performed on three different anatomical sites: lumbar spine (LS), left femur neck (FN), and left forearm (Arm). Bone health markers </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">(</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">bone alkaline phosphatase (BAP), osteocalcin, C-terminal telopeptide (CTX-I), deoxypyridinoline (DPD)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"> as well as immunological markers </span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">(</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">interleukin 6 (IL6) and immunoglobulin E (IgE)</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;">)</span></span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, were assessed in blood serum with enzyme immunoassays, at baseline and</span><span><span style="font-family:Verdana;"> 4-months after BC supplementation. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> No significant </span></span><span style="font-family:Verdana;">changes were found in bone densitometry factors (p > 0.05), for all studied blood parameters and their calculated effect sizes. </span><b><span style="font-family:Verdana;">Conclusions:</span></b><span style="font-family:Verdana;"> It is concluded that, as studied herein, BC does not seem to affect human bone health. This pilot study though warrant the need for further research into the efficacy of BC in patients with osteoporosis.
